技術支援室では、臨床研究等で得られた貴重な検体の処理及び保管管理、並びに当該検体を利用した新たな研究企画及び実施をしております。

連携機関

• SB新型コロナウイルス検査センター株式会社
• アボットジャパン合同会社
• キヤノンメディカルシステムズ株式会社
• 三洋化成工業株式会社、他

スタッフ紹介

更新日：2022年12月15日

役職	名前
技術支援室室長（併任)	木村　基, Moto KIMURA
上級研究員	竹内（柴田）潤子, Junko S. TAKEUCHI
上級研究員	深野　顕人, Kento FUKANO
特任研究員	神川　あずさ, Azusa KAMIKAWA
特任研究員	鬼頭　優美子, Yumiko KITO
研究補助員	有吉　希, Nozomi ARIYOSHI
研究補助員	波田野　恵美子, Emiko HATANO
研究補助員	髙橋　杏奈, Anna TAKAHASHI
事務助手	田村　良子, Ryoko TAMURA

実績

出版論文（技術支援室発足以降）

出版論文（査読付論文誌）

• [1] Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave.
  Yamamoto, S., K. Matsuda, K. Maeda, K. Horii, K. Okudera, Y. Oshiro, N. Inamura, J. S. Takeuchi, M. Konishi, M. Ozeki, T. Mizoue, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari. 2023.
  Int J Infect Dis. 2023 Jan 21 : S1201-9712(23)00023-1.
  https://doi.org/10.1016/j.ijid.2023.01.023.

• [2] SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study.
  Takeuchi, J. S., A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, A. Kamikawa, Y. Kito, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, and W. Sugiura (2022).
  Scientific Reports 12 (1): 15447.
  https://doi.org/10.1038/s41598-022-19581-y

• [3] Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
  Okumura, N., S. Saito, Y. Takamatsu, J. S. Takeuchi, Y. Asai, M. Sanada, N. Iwamoto, K. Maeda, H. Mitsuya, and N. Ohmagari (2022).
  J Infect Chemother 28 (12): 1704-1706.
  https://doi.org/10.1016/j.jiac.2022.08.026

• [4] Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA).
  Terayama, Y., N. Tomita, J. Terada-Hirashima, Y. Uemura, Y. Shimizu, J. S. Takeuchi, Y. Takamatsu, K. Maeda, A. Mikami, M. Ujiie, and W. Sugiura (2022).
  Life (Basel) 12 (7).
  https://doi.org/10.3390/life12070966

• [5] Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
  Okumura, N., S. Tsuzuki, S. Saito, S. I. Hattori, J. S. Takeuchi, T. Saito, M. Ujiie, M. Hojo, N. Iwamoto, W. Sugiura, H. Mitsuya, and N. Ohmagari (2022).
  J Infect Chemother 28 (9): 1340-1343.
  https://doi.org/10.1016/j.jiac.2022.04.018

• [6] An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
  Khor, S. S., Y. Omae, J. S. Takeuchi, A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, W. Sugiura, and K. Tokunaga (2022).
  Vaccines (Basel) 10 (4).
  https://doi.org/10.3390/vaccines10040563

• [7] Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
  Miyazato, Y., K. Yamamoto, Y. Nakaya, S. Morioka, J. S. Takeuchi, Y. Takamatsu, K. Maeda, M. Kimura, W. Sugiura, H. Mitsuya, M. Yano, and N. Ohmagari (2022).
  J Infect Chemother 28 (7): 991-994.
  https://doi.org/10.1016/j.jiac.2022.03.002

• [8] Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
  Yamamoto, S., A. Fukunaga, A. Tanaka, J. S. Takeuchi, Y. Inoue, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, W. Sugiura, and N. Ohmagari (2022.)
  Vaccine 40 (13): 1924-1927.
  https://doi.org/10.1016/j.vaccine.2022.02.052

• [9] Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
  Yamamoto, S., K. Maeda, K. Matsuda, A. Tanaka, K. Horii, K. Okudera, J. S. Takeuchi, T. Mizoue, M. Konishi, M. Ozeki, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari (2022).
  Clin Infect Dis 75 (1): e683-e691.
  https://doi.org/10.1093/cid/ciab1048

preprint

• [1]SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis.
  Yamamoto, S., K. Matsuda, K. Maeda, Y. Oshiro, N. Inamura, T. Mizoue, M. Konishi, J. S. Takeuchi, K. Horii, M. Ozeki, H. Sugiyama, H. Mitsuya, W. Sugiura and N. Ohmagari (2022).
  https://doi.org/10.1101/2022.06.21.22276682
  https://www.medrxiv.org/content/10.1101/2022.06.21.22276682v1